Causal attribution of smoking and BMI to the landscape of disease incidence in UK Biobank

Anthony J. Webster

Nuffield Department of Population Health, Big Data Institute, Old Road Campus, University of Oxford, Oxford, OX3 7LF, UK.

Methods from causal inference are combined with established epidemiological techniques, to estimate population attribution fractions for the influence of smoking and BMI on the risk of 226 different diseases in UK Biobank. Simple expressions for population attribution fractions are derived for this purpose, and evaluated using estimates from proportional hazard models. These are compared to the attribution fractions used by the World Health Organisation. A counterfactual argument is used to determine an individual's attribution fraction A_f in terms of proportional hazard estimates, finding $A_f = 1 - 1/R$, where R is an individual's relative risk. It is emphasised that causally meaningful attribution fractions cannot be constructed for all known risk factors or confounders, but there are important cases where they can. This includes the causal model that is assumed here to describe the influence of smoking and BMI on disease risk. The causal attribution of smoking and BMI to incidence of disease is summarised in terms of disease chapters from the International Classification of Diseases (ICD-10), and the diseases most strongly attributed to smoking and BMI are identified. The result is a quantitative characterisation of the causal influence of smoking and BMI on the landscape of disease incidence in the UK Biobank population.

1 Introduction

The aim of this research was to quantify and classify how patterns of disease incidence will be influenced by modifiable factors such as smoking and body mass index (BMI). Modifiable associations are often quantified with attributable fractions and relative risks [1, 2], that are estimated using proportional hazard models [2, 3]. However, there are several ways of defining and estimating attributable fractions [2, 4, 5], and estimates of relative risks do not generally have a causal interpretation [2].

Whereas statistics is the science of finding and describing patterns in data, epidemiology is the science of using statistics to make correct inferences. Although epidemiologists are careful to describe their results in terms of "associations", the purpose of epidemiology is to detect and quantify causal associations, e.g. between lifestyles and health [2, 8]. Recently the science of causal inference [6, 7, 9], has developed to identify circumstances where causal estimates are possible using observational data. The Methods show how the "backdoor criteria" and the "do" calculus [6, 7], can be used with estimates of relative risks from conventional epidemiological studies using proportional hazards [3]. It is shown that conventional estimates using observational data, will often correspond to estimates of causal associations. Situations that satisfy the "frontdoor" criteria, and their relationship to results from mediation analyses [9], are considered in the Supplementary Material. A population attribution fraction is developed to estimate the proportional change in disease incidence caused by a exposures in a population, that is expressed in terms of conventional proportional hazard estimates. It is valid when the estimates are of causal associations, in the sense outlined below and in the Methods. It is closely related to the average causal effect (ACE) [6, 7], and can (in principle), agree with existing expressions when these are combined with estimates of causal associations [1, 4]. An attribution fraction for an individual is also formulated using a counterfactual argument for the "effect of treatment on the treated" [6, 7], that gives a simple and well-known expression in terms of an individual's relative risk. Unless stated otherwise, the rest of this article will use "attribution fraction" to refer to the population attribution fraction.

The attribution of disease incidence to smoking and BMI was considered for the UK Biobank cohort of over 500,000 UK men and women [10]. Attribution fractions were estimated for 226 diseases with statistically significant associations after adjusting for multiple testing, using proportional hazards models that are adjusted for known confounding factors. The results emphasise the heterogeneous influence of risk factors, with protective associations for several diseases, but 11 with an attributable fraction in excess of 0.5 that should arguably be regarded as pathogenic. Diseases were characterised by their attribution fractions, that allowed them to be ranked and classified in terms of their risk modifiability in terms of smoking and BMI. The selection of diseases for study is detailed elsewhere [13], along with further information on the UK Biobank data that was used [10, 13]. In principle the estimates could be improved by studying each disease individually, but the study here accounts for the strongest confounding factors, while allowing a broad survey of the overall influence of smoking and BMI on disease.



Figure 1: Consider the influence of one or more exposures X, on diseases Y, with confounding variables Z that satisfy the "backdoor criteria" [6, 7] (figure a). For example, X might include BMI, alcohol, and smoking, with confounders Z of socio-economic status and education (figure b).

The causal model was assumed to be as in figure 1. The risk factors X are assumed to include smoking, BMI, and alcohol consumption, and the confounding factors Z are assumed to include education, socio-economic status, and for women only, HRT use and parity. The situation is described by the well-known "adjustment" formula [6, 7], that states,

$$P(Y = y|\text{do}(X = x)) = \sum_z P(Y = y|X = x, Z = z)P(Z = z) \tag{1}$$

where for continuous variables the sums are treated as integrals, upper case X, Y, Z correspond to specific values of random variables, and lower case x, y, z can take any allowed value. The formula accounts for the confounding influence of Z on both X and disease risk, and differs from the equivalent result from conventional probability theory, that would have $P(Z = z|X = x)$ instead of $P(Z = z)$. The Methods show how Eq. 1 can be used to form an attribution fraction to estimate the causal influence of smoking and BMI on disease risk. The estimates make use of the observation [12], that the diseases are rare, in the sense that we can approximate the cumulative distribution function for disease incidence $F(t, x, z)$ as $F(t, x, z) \simeq H(t, x, z)$ where $H(t, x, z)$ is the cumulative hazard function [3]. For diseases where the proportional hazards model can be used, this gives,

$$F(t, x, z) \simeq H(t) = e^{\eta_x + \eta_z} H_0(t) \quad \text{with} \quad H_0(t) = \int_0^t h_0(s)ds \tag{2}$$

where x are (a vector) of risk factors, y are (a vector) of confounding factors, t is time or age, and h_0 is the baseline hazard function [3]. An estimate for the (population) attribution fraction is shown to be,

$$A_f \simeq 1 - \frac{\sum_{i=1}^n e^{\eta_{w_i} + \eta_{z_i}}}{\sum_{i=1}^n e^{\eta_{x_i} + \eta_{w_i} + \eta_{z_i}}} \tag{3}$$

where η_x, η_z, η_w are linear predictors for the risk factors, confounders, and any risk factors (w) that we do not want to include in the attribution fraction, such as smoking and alcohol if we are only interested in BMI. It is also shown that if e^{η_x}, is uncorrelated with e^{η_z} and e^{η_w}, then an equivalent estimate for the attributable fraction used by the World Health Organisation [1] is,

$$A_f \simeq 1 - \frac{1}{\sum_{i=1}^n e^{\eta_{x_i}}} \tag{4}$$

which is smaller (greater) than Eq. 3 when e^{η_x} is positively (negatively) correlated with $e^{\eta_z + \eta_w}$.

Results

UK Biobank data [10] was used to estimate the attribution of smoking and BMI to the incidence of over 400 hospital diagnosed diseases in men and women. Diseases were characterised by their attribution fractions, allowing them to be ranked and classified in terms of their risk modifiability in terms of smoking and BMI. Frequency of alcohol consumption was adjusted for but not studied, because it is a comparatively imprecise measure, and is also found to have inconsistent

study-dependent associations with disease risk [19]. Information on the selection of diseases for study is detailed elsewhere [13], as are details of the UK Biobank cohort [10, 13]. Although the survival analyses could be improved by individual study of each disease, the study here accounts for the strongest confounding factors, while allowing a broad survey of the overall influence of smoking and BMI on disease.

Plots and tables include diseases with statistically significant associations with current smoking versus never smoked, or maximum versus middle BMI tertile, after an FDR multiple-testing adjustment. Where results involve both smoking and BMI then diseases were included if they are included in either of the smoking-only, or BMI-only results. This left 129 diseases associated with BMI, 153 diseases associated with smoking, and 226 diseases that were associated with either smoking or BMI. To explore the sensitivity of the estimates to the strength of confounding factors, estimates made using Eqs. 3 and 4 were compared (figure 2 in the Appendix). As expected, the influences of confounding are more noticeable for smaller attributable fractions, but even in those cases, the estimates rarely differ by more than about 20%. With a handful of exceptions, such as Parkinson's disease (G20), estimates with Eq. 3 were larger than with 4, as would be expected if the influence of smoking and BMI were positively correlated with the influence of the confounding factors in the model.



Figure 2: Median attributable fractions for each ICD-10 chapter with at least 5 diseases where $A_f > 0.2$. Bar widths are proportional to the number of diseases in each chapter.

Figure 2 shows the median attributable fractions for the combined influence of smoking and BMI on the incidence of disease in each ICD-10 chapter, with the width of the bar plots proportional to the number of diseases in the estimate. Diseases of the respiratory system (X) have the largest median attribution fraction, of about 0.3, closely followed by endocrine, nutritional, and metabolic diseases, that are both almost double the next largest values. Diseases of the skin and subcutaneous tissues (XII) and of the nervous system (VI), both have median attribution fractions near 0.15. Neoplasms and circulatory diseases account for 22% of all the diseases, and have the next largest median attributable fractions. There are seven chapters with median attribution fractions greater than 0.1, and these include 100 diseases, 50 of which are neoplasms and diseases of the circulatory system.

The 26% of diseases that had $A_f \geq 0.2$ are listed in table 1. There are 11 diseases with $A_f \geq 0.5$ and 21 with $A_f \geq 0.35$. Given the limitations of the analysis and the potential for regression dilution bias, it is possible that more than 11 diseases could have $A_f \geq 0.5$. For diseases with more than half the cases attributed to smoking and BMI, it seems reasonable to

regard smoking and BMI as "pathogenic", in a similar way that strong genetic risk factors are often described as pathogenic. One third of the 226 diseases had an attributable fraction with $|A_f| > 0.17$, and two thirds had $|A_f| > 0.06$. Although the mean attribution fraction for the combined influence of smoking and BMI was $\simeq 15\%$, the estimated attributable number of extra cases was only $\simeq 8\%$, reflecting the fact that the most common diseases (with the most cases), tended to have smaller attributable fractions.

Diseases were ranked in terms of their attribution fractions for smoking and BMI (figure 3). Figure 3 identifies an important point, that even established risk factors such as smoking and BMI can have protective associations with some diseases. The 20 diseases that smoking and BMI have the strongest protective associations with are listed in table 2. There were 12 diseases whose protective association had an attributable fraction with magnitude greater than 0.1, and 3 with magnitude greater than 0.2. Melanoma in situ (D03), had the strongest protective association of -0.29, where the sign is taken to indicate the direction of effect as discussed in "Number of attributed cases".



Figure 3: For diseases with a statistically significant association with smoking or BMI after an FDR multiple-testing adjustment, attributable fractions A_f were calculated with Eq. 21. Lines indicate $A_f = 0.5$ (red), $A_f = 0.35$ (orange), $A_f = 0.2$ (yellow). $A_f < 0$ indicates a protective association.

Sensitivity analysis

Participants with hospital reports of prior cancers other than non-melanoma skin cancers were excluded from the main study, but self-reported cancers or other prior diseases were not. It is possible for example, that a heart attack might be followed by weight loss, and including participants with prior heart attacks could weaken a potential association between BMI and heart disease. In contrast, smoking might increase the risk of some diseases for which a substantial proportion occur before entry into the UK Biobank study. In that case, including participants with the prior disease might strengthen the associations. The question of how best to study sequences of disease is an example where causal understanding is not enough, and new statistical methods or data are likely to be required. It might be an intractable question, due to the vast possible combinations of sequences of 100s of diseases, and it is further complicated by the complex time-dependent exposures and accumulation of genetic mutations that any individual experiences. Therefore a senstivity analysis compared the paper's main results with a second analysis that excluded participants who had reported any cancer other than non-melanoma skin cancer, or any serious cardiovascular disease of heart disease, stroke, arterial or pulmonary embolisms, or subarachnoid haemorrhage.

Disease	Sex	N	N_{A_f}	Rank	A_f	Rank A_f
E66 Obesity	F	311	306	24	0.98	1
J44.1 Chronic obstructive pulmonary disease with acute exacerbation, unspecified	F	209	193	53	0.92	2
J44.0 Chronic obstructive pulmonary disease with acute lower respiratory infection	F	416	376	17	0.90	3
J44.0 Chronic obstructive pulmonary disease with acute lower respiratory infection	M	417	374	18	0.90	4
J44.1 Chronic obstructive pulmonary disease with acute exacerbation, unspecified	M	261	230	41	0.88	5
C34 Malignant neoplasm of bronchus and lung	M	1018	833	4	0.82	6
I70 Atherosclerosis	M	156	114	86	0.73	7
C34 Malignant neoplasm of bronchus and lung	F	996	710	6	0.71	8
E11 Non-insulin-dependent diabetes mellitus	M	206	114	86	0.55	9
I71 Aortic aneurysm and dissection	M	402	222	44	0.55	10
R04.2 Haemoptysis	M	314	162	60	0.52	11
C15 Malignant neoplasm of oesophagus	M	473	220	46	0.47	12
R91 Abnormal findings on diagnostic imaging of lung	M	358	162	60	0.45	13
C67 Malignant neoplasm of bladder	M	1063	438	9	0.41	14
R91 Abnormal findings on diagnostic imaging of lung	F	372	151	65	0.41	15
I50 Heart failure	F	280	111	88	0.40	16
K42 Umbilical hernia	F	297	111	88	0.37	17
G47.3 Sleep apnoea	F	381	139	69	0.36	18
J84 Other interstitial pulmonary diseases	F	177	63	117	0.35	19
I50 Heart failure	M	359	125	75	0.35	20
R04.2 Haemoptysis	F	239	83	103	0.35	21
J10 Influenza due to identified influenza virus	F	211	69	114	0.33	22
M13 Other arthritis	M	215	70	112	0.32	23
R29.6 Tendency to fall, not elsewhere classified	M	182	58	123	0.32	24
A41 Other septicaemia	F	957	303	25	0.32	25
J18 Pneumonia, organism unspecified	M	3011	944	2	0.31	26
C22 Malignant neoplasm of liver and intrahepatic bile ducts	M	171	54	126	0.31	27
L72.0 Epidermal cyst	M	456	139	69	0.30	28
J18 Pneumonia, organism unspecified	F	2777	845	3	0.30	29
G47.3 Sleep apnoea	M	776	236	39	0.30	30
N17 Acute renal failure	F	333	99	94	0.30	31
G44.2 Tension-type headache	F	152	44	135	0.29	32
K43 Ventral hernia	F	377	108	90	0.29	33
G62 Other polyneuropathies	M	175	50	130	0.29	34
C16 Malignant neoplasm of stomach	M	260	70	112	0.27	35
B37 Candidiasis	M	173	47	132	0.27	36
R06.0 Dyspnoea	M	650	176	58	0.27	37
I26 Pulmonary embolism	F	836	225	43	0.27	38
R63.4 Abnormal weight loss	F	485	125	75	0.26	39
J84 Other interstitial pulmonary diseases	M	234	60	119	0.26	40
J22 Unspecified acute lower respiratory infection	F	1506	386	15	0.26	41
E87.1 Hypo-osmolality and hyponatraemia	M	234	59	120	0.25	42
I25.9 Chronic ischaemic heart disease, unspecified	M	254	63	117	0.25	43
M48 Other spondylopathies	F	573	139	69	0.24	44
K62.1 Rectal polyp	M	1143	275	32	0.24	45
N17 Acute renal failure	M	562	135	71	0.24	46
H02.4 Ptosis of eyelid	M	253	59	120	0.23	47
C90 Multiple myeloma and malignant plasma cell neoplasms	F	247	58	123	0.23	48
M47 Spondylosis	M	338	79	105	0.23	49
L60 Nail disorders	F	236	55	125	0.23	50
R13 Dysphagia	M	959	218	47	0.23	51
J90 Pleural effusion, not elsewhere classified	M	524	119	82	0.23	52
J22 Unspecified acute lower respiratory infection	M	1349	300	27	0.22	53
L03 Cellulitis	M	2036	450	8	0.22	54
M81 Osteoporosis without pathological fracture	F	946	204	50	0.22	55
K92.0 Haematemesis	M	156	33	152	0.21	56
L03 Cellulitis	F	1602	333	21	0.21	57
K25 Gastric ulcer	M	338	70	112	0.21	58
I64 Stroke, not specified as haemorrhage or infarction	M	173	35	148	0.20	59

Table 1: Attributable fractions A_f for both smoking and BMI are estimated with Eq. 21, ranked, and listed if $A_f \geq 0.2$. Colours: $A_f \geq 0.5$ (red), $0.5 > A_f \geq 0.35$ (orange), $0.35 > A_f \geq 0.2$ (yellow). Sex: diseases in males (M) or females (F), N: total cases, N_{A_f}: attributed cases.

Disease	Sex	N	N_{A_f}	Rank	A_f	Rank A_f
D03 Melanoma in situ	M	272	−79	14	−0.290	1
K31.7 Polyp of stomach and duodenum	F	870	−212	9	−0.240	2
N41 Inflammatory diseases of prostate	M	572	−114	10	−0.200	3
N81 Female genital prolapse	F	4199	−819	1	−0.190	4
R79 Other abnormal findings of blood chemistry	M	1905	−333	5	−0.170	5
S02 Fracture of skull and facial bones	M	355	−57	18	−0.160	6
C43 Malignant melanoma of skin	M	723	−96	11	−0.130	7
S76.1 Injury of quadriceps muscle and tendon	M	215	−24	25	−0.110	8
M20.1 Hallux valgus (acquired)	F	2875	−307	6	−0.110	9
C61 Malignant neoplasm of prostate	M	5800	−521	2	−0.090	10
B34 Viral infection of unspecified site	M	319	−28	23	−0.089	11
N40 Hyperplasia of prostate	M	3928	−344	4	−0.088	12
M16 Coxarthrosis [arthrosis of hip]	M	3167	−272	7	−0.086	13
J90 Pleural effusion, not elsewhere classified	F	327	−28	23	−0.084	14
K40 Inguinal hernia	F	493	−39	20	−0.079	15
R19.8 Other specified symptoms and signs involving the digestive system and abdomen	F	302	−22	27	−0.072	16
C44 Other malignant neoplasms of skin	M	6095	−391	3	−0.064	17
K31.7 Polyp of stomach and duodenum	M	300	−17	31	−0.057	18

Table 2: Diseases with the strongest protective associations, ranked by the proportion of disease attributed to a combination of smoking and BMI (A_f). Sex indicates diseases in males (M) or females (F), N are total cases, N_{A_f} are the number of cases attributed to smoking and BMI, A_f is the attributable fraction.

Disease	Sex	N	N_{A_f}	Rank	A_f	Rank A_f
S00.8 Superficial injury of other parts of head	F	171	39	135	0.23	44
S92 Fracture of foot, except ankle	M	168	38	138	0.22	46
E21 Hyperparathyroidism and other disorders of parathyroid gland	F	296	66	106	0.22	48
I21 Acute myocardial infarction	F	1125	243	28	0.22	50
M79.6 Pain in limb	F	920	198	41	0.22	51
M17 Gonarthrosis [arthrosis of knee]	F	3623	735	3	0.20	57

Table 3: The sensitivity analyses found six additional diseases with $A_f \geq 0.2$, for the combination of both smoking and BMI, that would have appeared in table 1. Sex: diseases in males (M) or females (F), N: total cases, N_{A_f}: attributed cases.

Differences between the main study and the sensitivity analysis were small. There were six diseases whose attribution fractions increased from $A_f < 0.2$, to $A_f \geq 0.2$, these are listed in table 3. The difference between attribution fractions in the two studies had a mean and median of -0.006 and -0.005 respectively, and a standard deviation of 0.029. The differences in magnitude were typically equivalent to about 10%. The attribution fractions of six diseases changed by more than 0.05. These included increased attributable fractions for: I50 - heart failure in women (0.40 to 0.48), R29.6 - tendency to fall in men (0.32 to 0.41), and decreases in: C16 - stomach cancer in men (0.27 to 0.21), J10 - influenza in women (0.33 to 0.27), J22 - lower respiratory infections in men (0.24 to 0.17), and N17 - acute renal failure (0.24 to 0.17).

Discussion

Effect of treatment on the treated (ETT)

An alternative attribution fraction, that is of more interest to clinicians or an individual, is the chance of having avoided a disease if you had not been exposed, but were subjected to the same confounding factors that you would have otherwise experienced. This situation is equivalent to estimating the "effect of treatment on the treated" (ETT) [6, 7], but the "treatment" is an exposure to smoking or BMI. For the situation considered here of figure 1, this counterfactual question can be formulated and expressed in terms of observational quantities in a similar way to before. The argument below considers the simpler situation of smokers versus never smoked, or max BMI tertile versus a lower BMI tertile, denoting exposed by $X = x_1$ and unexposed by $X = x_0$. Using counterfactual notation where Y_{x_1} indicates the disease status of (e.g.) smokers, and Y_{x_0} the

disease status of non-smokers, then the ETT is defined as [6, 7],

$$ETT = E\left[Y_{x_1} - Y_{x_0} | X = x_1\right] \tag{5}$$

that can be thought of as estimating the difference between disease risk in smokers and non-smokers, when subjected to the same correlated confounding influences as smokers would experience. Following a previous derivation [7], and incorporating the same proportional hazards assumptions as before, this can be written as,

$$\begin{aligned} ETT &= P(Y_{x_1} = 1 | X = x_1) - P(Y_{x_0} = 1 | X = x_1) \\ &= \int P(Y = 1 | W = w, Z = z, X = x_1) P(W = w, Z = z | X = x_1) dw dz \\ &\quad - \int P(Y = 1 | W = w, Z = z, X = x_0) P(W = w, Z = z | X = x_1) dw dz \\ &= H_0(t) e^{\eta_{x_1}} \int e^{\eta_w + \eta_z} P(W = w, Z = z | X = x_1) dw dz - H_0(t) e^{\eta_{x_0}} \int e^{\eta_w + \eta_z} P(W = w, Z = z | X = x_1) dw dz \end{aligned} \tag{6}$$

where the second term on the second line is usually justified with the backdoor adjustment formula Eq. 8, but corresponds to estimating the probability of disease when $X = x_0$ but all other exposures are as they would have been if $X = x_1$, and the third line uses the approximation of sufficiently rare diseases that the cumulative distribution function can be approximated by the cumulative hazard. Continuing to take the baseline value $e^{\eta_{x_0}} = 1$, and dividing by the first term to get an attribution fraction, then gives,

$$A_{ETT} = \frac{e^{\eta_{x_1}} - 1}{e^{\eta_{x_1}}} \tag{7}$$

which solely involves the relative risk $R = e^{\eta_{x_1}}$ for e.g. smoking status, and is the simplest attribution fraction that occurs in the literature.

Because survival analyses are designed to estimate the influence of risk on an individual, with hindsight, perhaps Eq. 7 should not have been a surprise? Within the proportional hazards model, smoking will modify your risk of disease, independently of whether any other factors also do. From a population perspective, disease risk is determined by the overall combination of exposures, that will usually be correlated. This is why the attribution fraction for the population needs a more careful estimation that accounts for correlations between the exposures and confounding variables.

Attribution fractions for causal estimates

Attribution formulae similar to those used here have existed in published literature since at least 1998 [4]. One aim of this paper is to emphasise that for a given causal model such as that in figure 1, the attribution fractions can only be used with a restricted range of potential risk modifiers, whose associations have a causal interpretation. If the causal model is incorrect, then the adjustment for confounding, and resulting estimates, are also likely to be incorrect. Alternately, if the measurement is too imprecise e.g. socio-economic status is likely to capture the influence of several factors that may include exposure to pollution, poor quality diet, poor living and working conditions, etc, then it may not be possible to estimate a meaningful causal association - for example, someone with an equivalent socio-economic status in a different country would experience different exposures and have different causal factors that influence their health. Another observation is that it may not be possible to obtain estimates of causal associations from a single analysis, but it might be possible to use the causal diagram to design an analysis that can estimate the parameters you are interested in. For example, changes in systolic blood pressure (SBP) can be caused by smoking or BMI, and therefore SBP should not be adjusted for if we are interested in the influence of smoking and BMI on disease risk. In contrast, if our interest was in SBP, then we would need to adjust for BMI and smoking if they can modify disease risk in any way other than through changes in SBP.

Attribution of disease to smoking and BMI

The attribution fractions for smoking, and BMI, are very heterogeneous, and can involve a reduction in risk (table 2). This highlights a difficulty in optimising lifestyle and drug treatments - changes in lifestyle or medication are likely to have a very heterogeneous influence on disease risk, with some risks lowered but others potentially increased. Another observation was that some of the associations were extremely strong, for example with $A_f > 0.5$. Strong germline genetic risk factors are often described as pathogenic when they substantially increase your risk of disease, and it seems reasonable to describe the influence of risk factors as pathogenic when A_f is large, such as $A_f > 0.5$. For diseases estimated to have $A_f > 0.5$, eliminating the risk factors would be estimated to prevent the majority of those diseases in an equivalent population.

Attribution fractions can identify diseases for which lifestyle changes are likely to have the greatest impact. From a population perspective, eliminating smoking and controlling BMI in an equivalent population would be expected to avoid: the majority of diseases with $A_f > 0.5$ (red in table 1), between one third and one half of diseases with $0.35 > A_f > 0.5$ (orange in table 1), between one fifth and one third of diseases with $0.2 > A_f > 0.35$ (yellow in table 1). This slightly ad-hoc categorisation provides an indication of how the patterns of disease would be expected to change if smoking were eliminated and BMI were controlled in a population that was otherwise similar to that in UK Biobank.

Attributable fractions for a population will be larger if more of the population are exposed to a harmful risk factor. The Supplementary Material considers an example with a binary exposure X that is uncorrelated with W and confounders Z, and shows that provided $p(R-1) \ll 1$, where R is the relative risk and p is the proportion of the population that are exposed, then $A_f \simeq p(R-1)$. In that case, if the exposed proportion p were halved, then so would the attributable fraction. This highlights an important characteristic of Eqs. 3 and 4 - they measure the proportion of disease in a population that is attributed to an exposure. However, a clinician might be more interested in the proportion of disease in smokers is attributable to smoking, and an individual might be more interested in whether smoking substantially changes their risk of serious disease or death. Questions that refer to individuals can be tackled with counterfactual arguments and Eq. 7. An alternative approach is to consider the "probability of necessity" [6, 7], that is intended to assess whether it is more probable than not, that the disease would not have occurred if you had not been exposed to e.g. smoking. Such approaches allow specific individual cases to be assessed, but do not provide an overall characterisation of an exposure's influence on population health.

When considering attribution fractions for smoking and BMI together, the study included diseases with statistically significant associations with *either* smoking or BMI. In this situation, especially when the number of cases are few, estimates for one of the two parameters can in principle be large and imprecise. This could produce misleading estimates for the joint attribution fraction of both smoking and BMI. An example is the strong protective association of smoking with Parkinson's disease (table 4 in the Supplementary Material), that was substantially weakened by the association with BMI (table 2), even though the association with BMI was not statistically significant. This appears to be an isolated example, and the potential problem is less likely with more cases, but it highlights the importance of also considering the attribution fractions for each separate exposure.

Meta analyses

If estimates form observational data are to be used in meta-analyses, then it is essential to ensure that estimates are of causal associations. Some reported estimates will measure the causal influence of a potential risk factor, such as BMI, alcohol, and smoking in the first example considered here, but this is unlikely to be true for all variables that are adjusted for. If a study has inappropriately adjusted for potential confounding variables, then the data should not be included in the meta-analysis. To assess this, a sufficiently good causal understanding is needed of how risk factors and confounders modify disease risk. Disagreement between studies may indicate incomplete understanding of the underlying causal model, with inappropriate or insufficient adjustment for confounding factors. In the common situation where uncertainty of the causal processes linking exposure X to disease risk remain, then the standard methods and cautious reporting of conventional epidemiology must remain [2, 8], and data from these observational studies cannot reliably be used in meta-analyses.

Conclusions

The aim was to characterise and classify the causal influence of established risk factors on common diseases, using observational data from UK Biobank. Assuming a simple causal model (figure 1), the theory of causal inference allows the estimation of causal associations from observational data, for some but not all factors that are usually included in epidemiological studies. These included smoking and BMI. The "backdoor criteria" from causal inference was used to derive a population attribution fraction, and it was shown how proportional hazards estimates can be used for its evaluation. Conventional epidemiological methods using proportional hazards were used to estimate (adjusted) associations between established risk factors and common diseases in UK Biobank data. The estimates were used to evaluate attribution fractions for smoking and BMI on the incidence of 226 diseases, identifying the diseases and ICD-10 chapter disease classifications whose risks were the most modifiable. The results indicate which diseases and classes of diseases in the UK Biobank cohort are the most strongly influenced by smoking and BMI, and provides a template for more comprehensive future studies.

Methods

Relative risks and the "backdoor criteria"

Adjustment was made for associations with smoking, BMI, alcohol consumption, education, socio-economic status, and for women only, for HRT use and whether they have given birth. Figure 1 shows the assumed causal relationships. The risk factors X are assumed to include smoking, BMI, and alcohol consumption, and the confounding factors Z are assumed to include education, socio-economic status, and for women only, HRT use and parity. The presence or absence of disease is indicated by $Y = 1$ or $Y = 0$. For this causal model (figure 1), it is possible to estimate the consequences of setting BMI, alcohol, and smoking to a specific value $X = x$, corresponding to do$(X = x)$ using the "do" notation of Pearl [6, 7]. The situation is described by the well-known "adjustment" formula [6, 7], that states,

$$P(Y = y|\text{do}(X = x)) = \sum_z P(Y = y|X = x, Z = z)P(Z = z) \tag{8}$$

where for continuous variables the sums are treated as integrals, upper case X, Y, Z correspond to specific values of random variables, and lower case x, y, z can take any allowed value. The formula accounts for the confounding influence of Z on both X and disease risk, and differs from the equivalent result from conventional probability theory, that would have $P(Z = z|X = x)$ instead of $P(Z = z)$. Take $Y = 1$ to denote presence of disease, and $Y = 0$ its absence, so that,

$$P(Y = 1, T < t|X = x, Z = z) = F(t, x, z) \tag{9}$$

where $F(t, x, z)$ is the distribution function (with covariates x, z), so that,

$$\begin{aligned} F(t,x,z) &= 1 - S(t,x,z) \\ &= 1 - \exp(-H(t,x,z)) \\ &\simeq H(t,x,z) \\ &= e^{\eta_x+\eta_z} H_0(t) \quad \text{with} \quad H_0(t) = \textstyle\int_0^t h_0(s)ds \end{aligned} \tag{10}$$

where in going from the 2nd to 3rd line we assume sufficiently rare diseases that $\exp(-H(t, x, z)) \simeq 1 - H(t, x, z)$, as is the case for the first diagnosis of most diseases in UK Biobank [10, 12], and in going from the 3rd to the 4th lines we assume that the proportional hazards assumption [3] is valid for the disease being studied, with η_x and η_z being the linear predictor functions[1] for the (possibly) multivariate variables x and z. For a probability density $f = dF/dt$ and hazard function $h = f/S$, $H(t) = \int_0^t h(t)$ is the cumulative hazard, and a proportional hazards model assumes that $h(t, x, z) = h_0(t)e^{\eta_x+\eta_z}$. Now using Eq. 8,

$$\begin{aligned} &P(Y = 1, T < t|\text{do}(X = x)) \\ &= \textstyle\sum_z P(Y = y, T < t|X = X, Z = z)P(Z = z) \\ &\simeq \textstyle\sum_z e^{\eta_x+\eta_z} H_0(t)P(Z = z) \\ &= e^{\eta_x} H_0(t)A_Z \end{aligned} \tag{11}$$

with $A_Z \equiv \sum_z e^{\eta_z} P(Z = z)$. This allows the incidence rates to be calculated for a (possibly hypothetical) situation where we have intervened in some way to set $X = x$, in terms of a baseline hazard function that is estimated in the usual way, using observational data in which Z can be correlated with both X and disease risk. Note that $P(Z = z)$ and $P(X = x)$ are implicitly the population values at the study's start.

At the baseline values of $x = x_0$ and $z = z_0$, by definition $\eta_x(x_0) = 0$ and $\eta_z(z_0) = 0$, so Eq. 11 gives $P(Y = 1, T < t|X = x_0, Z = z_0) = H_0(t)$. Then using the same approximations used to derive Eq. 11, it can be written in several ways, for example,

$$\begin{aligned} &P(Y = 1, T < t|\text{do}(X = x)) \\ &= e^{\eta_x} A_Z H_0(t) \\ &= e^{\eta_x} A_Z P(Y = 1, T < t|X = x_0, Z = z_0) \\ &= A_Z P(Y = 1, T < t|X, Z = z_0) \end{aligned} \tag{12}$$

When education and socio-economic factors are represented by Z, then the factor A_Z accounts for changes in risk due to both socio-economic factors and education, and the influence of setting $X = x$ is calculated through the factor e^{η_x}. If we

[1] For a particular $X = x$, the linear predictor function is sometimes referred to as the "linear component", "risk score", or "prognostic index" [3].

could set X equal to the baseline values x_0, the probability distribution would be proportional to the baseline hazard function $H_0(t)$, amplified or shrunk by the factor A_Z. If the baseline values corresponded to the lowest disease risk, then $A_Z H_0(t)$ would be the lowest possible disease incidence rate that could have been achieved through lifestyle changes. Eq. 12 can be written as,

$$\frac{P(Y=1,T<t|\text{do}(X=x))}{P(Y=1,T<t|\text{do}(X=x_0))} = e^{\eta_x} \tag{13}$$

This gives a relative risk of disease within time t for a population with $X=x$, compared with a population with baseline values of $X=x_0$, in terms of estimates from a relative risk from observational studies, that have,

$$e^{\eta_x} = \frac{h(t|X=x,Z=z_0)}{h(t|X=x_0,Z=z_0)} \tag{14}$$

The analysis above applies more generally to other examples, and to studies other than those involving disease or health. Similar results will apply whenever $F(t,x,z)$ can be factored as $H_0(t)g(x)q(z)$, for some functions $g(x)$ and $q(z)$, as was possible here because we consider a proportional hazards model and situations whose the incidence is sufficiently rare that we can approximate $F(t,x,z) \simeq H(t,x,z)$.

Attributable fractions

Attributable fractions are intended to describe the proportion of disease incidence that is caused by an exposure, or can be avoided by an intervention. They can be defined in several related but distinct ways [2, 5]. Here the attributable fraction for the situation described by figure 1 is considered. To allow exploration of the causal influence of a subset X, of risk factors X and W, the risk factors are considered to be composed of both X and W. If $P(Y=1,T<t)$ is the probability of observing a disease at a time T, less than t, then the average causal effect of risk factors on disease risk in a population compared with baseline risk factors is, $P(Y=1,T<t) - P(Y=1,T<t|\text{do}(X=x_0))$, and the excess fraction is,

$$A_f = \frac{P(Y=1,T<t) - P(Y=1,T<t|\text{do}(X=x_0))}{P(Y=1,T<t)} \tag{15}$$

The numerator of 15 is the average causal effect (ACE) [6] of the risk factors X on the population's disease risk, compared with the baseline values $X=x_0$. It is divided by the probability of risk in the population, giving an excess risk fraction, that is referred to here as an attributable fraction. To evaluate this, firstly note that,

$$\begin{aligned} P(Y=1,T<t) &= \int dxdwdz\ P(Y=1,T<t,X=x,W=w,Z=z) \\ &= \int dxdwdz\ P(Y=1,T<t|X=x,W=w,Z=z)P(X=x,W=w,Z=z) \\ &\simeq H_0(t) \int dxdwdz\ e^{\eta_x+\eta_w+\eta_z} P(X=x,W=w,Z=z) \end{aligned} \tag{16}$$

where we assumed the data could be described by a proportional hazards model, and has sufficiently rare diseases to allow the approximation $F(t) \simeq H(t) = H_0(t)e^{\eta_x+\eta_w+\eta_z}$, where η_x, η_w, η_z are linear predictors respectively involving x, w, and z. Integrals should be replaced by sums for non-continuous variables. $P(Y=1,T<t|\text{do}(X=x_0))$ can be evaluated similarly, and for the example of figure 1 considered here, we can use the backdoor adjustment formula in the second line below,

$$\begin{aligned} P(Y=1,T<t|\text{do}(X=x_0)) &= \int dwdz\ P(Y=1,T<t,W=w,Z=z|\text{do}(X=x_0)) \\ &= \int dwdz\ P(Y=1,T<t|X=x_0,W=w,Z=z)P(W=w,Z=z) \\ &\simeq H_0(t)e^{\eta_{x_0}} \int dwdz\ e^{\eta_w+\eta_z} P(W=w,Z=z) \end{aligned} \tag{17}$$

Therefore, using Eqs. 16 and 17, the excess fraction is given by,

$$A_f = \frac{\int dxdwdz\ e^{\eta_x+\eta_w+\eta_z} P(X=x,W=w,Z=z) - e^{\eta_{x_0}} \int dxdwdz\ e^{\eta_w+\eta_z} P(W=w,Z=z)}{\int dxdwdz\ e^{\eta_x+\eta_w+\eta_z} P(X=x,W=w,Z=z)} \tag{18}$$

where $e^{\eta_{x_0}} = 1$ for the baseline variables x_0. The equation is very similar to conventional expressions for attributable fractions that use relative risks [5], that would give an attributable fraction of $1-1/R = 1-e^{-\eta_x}$, where R is the relative risk.

However the expression now involves averages over the population, that include potential correlations with the confounding variables. The WHO uses an attributable fraction that is defined as [1],

$$A_W = \frac{\int dx\, e^{\eta_x} P(X=x) - \int dx\, e^{\eta_x} P'(X=x)}{\int dx\, e^{\eta_x} P(X=x)} \tag{19}$$

where $P'(X=x)$ is an alternative probability distribution for X. If we take $P'(X=x)$ to be a delta function centred on $X=x_0$, with $e^{x_0}=1$, so that we are comparing the population with one where $X=x_0$, then,

$$A_W = 1 - \frac{1}{\int dx\, e^{\eta_x} P(X=x)} \tag{20}$$

which is the same as would be obtained by assuming that e^{η_x} and $e^{\eta_w+\eta_z}$ are uncorrelated in Eq. 18. Appendix A.1 shows that the A_W provides a lower (upper) bound on A_f if e^{η_x} is positively (negatively) correlated with $e^{\eta_w+\eta_z}$. In general Eqs. 18 and 19 will differ, and neither should have a causal interpretation unless the causal model satisfies suitable conditions such as those in figure 1 that ensure that causal associations are being estimated.

To estimate the integrals in 18, note that $E[f(X)] = E[(1/n)\sum_{i=1}^n f(X_i)]$ and that the variance $\text{Var}[(1/n)\sum_{i=1}^n f(X_i)] = (1/n)\text{Var}(f(X)) \to 0$ as $n \to \infty$. This allows the integrals to be approximated by a sum over the observed data, which is reasonable if the number of data points is sufficiently large in each level of categorical data considered. For example, in the study of UK Biobank described later with nearly 500,000 participants, the smallest category was for current smokers, but this included over 50,000 smokers. With this approximation,

$$A_f \simeq 1 - \frac{\sum_{i=1}^n e^{\eta_{w_i}+\eta_{z_i}}}{\sum_{i=1}^n e^{\eta_{x_i}+\eta_{w_i}+\eta_{z_i}}} \tag{21}$$

That might alternately be written as,

$$A_f = 1 - \frac{1}{\sum_{i=1}^n w_i e^{\eta_{x_i}}} \tag{22}$$

with,

$$w_i = \frac{e^{\eta_{w_i}+\eta_{z_i}}}{\sum_{i=1}^n e^{\eta_{w_i}+\eta_{z_i}}} \tag{23}$$

which shows that the relative risk is weighted by the influence of confounders and other risk factors, but is similar to conventional expressions attributable fractions with $A = 1 - e^{-\eta_{x_i}}$. When there are no confounders or other risk factors than x, then the terms in Eq. 23 become 1, and $w_i = 1/n$, so that $\sum_{i=1}^n w_i e^{\eta_{x_i}}$ is then just the average of $e^{\eta_{x_i}}$ across the population. The expression makes it clear that if the relative risk $e^{-\eta_{x_i}}$ is positively correlated with the relative risks from the confounding and other potential risk factors $e^{\eta_{w_i}+\eta_{z_i}}$, then $\sum_{i=1}^n w_i e^{\eta_{x_i}} > \sum_{i=1}^n e^{\eta_{x_i}}$, and the attribution fraction is greater when accounting for the confounding and other potential risk factors.

To compare the attributable risk between setting $X=x_1$ and $X=x_2$, the equivalent expression to Eq. 21 is,

$$\frac{P(Y=1,T<t|\text{do}(X=x_2)) - P(Y=1,T<t|\text{do}(X=x_1))}{P(Y=1,T<t|\text{do}(X=x_2))} = 1 - \frac{e^{\eta_{x_1}}\sum_{i=1}^n e^{\eta_{w_i}+\eta_{z_i}}}{e^{\eta_{x_2}}\sum_{i=1}^n e^{\eta_{w_i}+\eta_{z_i}}} = 1 - e^{\eta_{x_1}-\eta_{x_2}} \tag{24}$$

which is just the conventional result for attributable fraction in terms of the relative risk.

Number of attributed cases

The proportion of disease cases that are attributed to a risk factor is only important if the disease is sufficiently common. The change in the number of cases of disease can be estimated using the estimated attributable fraction and the number of observed cases of disease. If N is the population size under consideration, and $P \equiv P(Y=1,T<t)$, $P_0 \equiv P(Y=1,T<t|\text{do}(X=x_0))$, then,

$$A_f = \frac{N(P-P_0)}{NP} \tag{25}$$

If we approximate NP as the observed number of cases in the population being studied N_{obs}, then we can estimate the number of extra (or fewer) cases from the attributable fraction A_f, with,

$$N_{A_f} \equiv N(P-P_0) = A_f NP \simeq A_f N_{obs} \tag{26}$$

This gives a simple estimate for the number of cases that are attributable to a risk factor. However, this is the number of attributable cases of hospital admissions, for diseases included by the study's selection criterion - first admissions in an ICD-10 chapter in this paper. This latter estimate could substantially differ from our perception of the number of hospital admissions caused by a specific disease, that could be dominated by sequences of hospital visits, or result from a different original underlying cause. For that reason, attributable fractions are generally a better measure of the causal influence of risk factors on the risk of disease.

If the attributable fraction given by Eq. 21 were negative, then instead of considering $(P - P_0)/P$, an alternative would be to consider $(P_0 - P)/P_0$. However, provided A_f is reasonably small, then the two estimates have approximately the same magnitude, with a change in sign to indicate the direction of effect. Expanding $(P_0 - P)/P_0$ in terms of $A_f = (P - P_0)/P$, gives,

$$\frac{P_0 - P}{P_0} = -\left(\frac{P - P_0}{P}\right)\frac{1}{1 - \left(\frac{P - P_0}{P}\right)} \simeq -\left(\frac{P - P_0}{P}\right)(1 + A_f) \tag{27}$$

Showing that both expressions are approximately equal in magnitude if A_f is small.

Survival analysis

To minimise the potential for confounding by prior disease, only the first incidence of disease in each ICD-10 chapter was considered for each individual. Diagnoses that were the primary cause of hospital admission were considered. These will have passed a threshold of severity to trigger hospital admission, and are recorded with an ICD-10 code in hospital episode statistics (HES). Individuals who reported diabetes at entry to the study were excluded, to ensure that any new cases of diabetes would almost entirely involve type II diabetes. For each disease, the participant's data were excluded if onset occurred before they entered the study, or if they had a prior hospital diagnosis of cancer other than non-melanoma skin cancer. The incidence rates of the diseases considered are "rare" in the approximate sense needed to estimate attribution fractions [12]. A survival analysis using age as the time variable was left-truncated at a participant's entry to the study, right-censored if there was: death, cancer other than non-melanoma skin cancer, or the study period ended. All diagnoses recorded between entering the study and 31st January 2020 were included, as recorded in UK Biobank HES data on 8th December 2021. Data beyond 31st January 2021 were likely to be influenced by the COVID-19 pandemic and were omitted. Analyses were multiply adjusted using a proportional hazards model, with men and women studied separately, and a causal model assumed as in figure 1. Adjustment considered the established risk factors of: smoking status (never, previous, or current), alcohol consumption (rarely - less than 3 times per month, sometimes - less than 3 times a week but more than 3 per month, regularly - 3 or more times each week), education (degree level, post-16 but below degree, to age 16 or unspecified), socio-economic status (tertiles), height (sex-specific tertiles), BMI (sex-specific tertiles), and for women we also adjusted for: HRT use ever (yes, no), and one or more children (yes,no). Baseline was taken as: never smoker, rarely drink, brisk walking pace, degree-level education, minimum deprivation tertile, minimum height tertile in men (or women), middle BMI tertile in men (or women), and women with no children or HRT use. Only diseases with at least 140 cases were considered. This ensured there were at least 10 cases per parameter to adjust from baseline, even if a parametric e.g. Weibull model with an extra two parameters to fit the baseline hazard function were considered [12]. Sensitivity analyses excluded participants with a broader range of prior diseases, leading to fewer total cases and fewer diseases included in the study. Analyses were multiply adjusted. There were less than 1% missing values, allowing a complete case analysis. Numerical work and plots used R [15], and packages used here included: survival[16] and grr[17].

Attribution fractions for the UK Biobank population were considered for three situations: observed population verus never-smoked, observed population versus middle BMI tertile, and observed population versus never-smoked and middle BMI tertile. The latter case is comparing the correlated exposures of BMI and smoking status in the observed population, to a situation where BMI and smoking are set to their baseline values of never-smoked and middle BMI tertile. Because the baseline BMI tertile is the middle tertile, current smokers could be correlated with either the top or bottom BMI tertile. Frequency of alcohol consumption was adjusted for but not studied, because it is a less precise measure than smoking status or BMI, and it is known to have inconsistent associations with disease risk in different studies [19].

Data availability

UK Biobank data can be accessed by application through www.ukbiobank.ac.uk, and summary data produced during this study will become available from: osf.io/. UK Biobank has approval by the Research Ethics Committee (REC) under approval number 16/NW/0274. UK Biobank obtained participant's consent for the data to be used for health-related research, and all methods were performed in accordance with the relevant guidelines and regulations.

Code availability

R code used to produce figures from summary data will become available from: osf.io/. The full code for use with non-summary data will be returned with other results to UK Biobank (see www.ukbiobank.ac.uk).

Acknowledgements

Thank you to Professor Robert Clarke for suggesting a sensitivity analysis to strengthen the results. This research has been conducted using the UK Biobank resource under application number 42583. Anthony Webster is supported by an intermediate research fellowship from the Nuffield Department of Population Health (NDPH), University of Oxford.

Competing interests

The author declares no competing interests.

References

[1] World Health Organization, *Global health risks: mortality and burden of disease attributable to selected major risks*, World Health Organization (2009).

[2] T.L. Lash, T.J. VanderWeele, S. Haneuse, K.J. Rothman, *Modern Epidemiology*, Fourth Edition, Wolters Kluwer, (2021).

[3] D. Collett *Modelling Survival Data in Medical Research*, New York: Chapman and Hall/CRC, 3rd edition, (2014).

[4] Rockhill, B. Newman, B. and Weinberg, C. *Use and misuse of population attributable fractions* American Journal of Public Health, **88**, 15-19, (1998).

[5] M.A. Mansournia, A. Douglas G, *Population attributable fraction*, BMJ - British Medical Journal, **360**, k757, (2018).

[6] J. Pearl *Causality*, 2nd ed., John Wilely & Sons Ltd, (2009).

[7] J. Pearl, M. Glymour, N.P. Jewell, *Causal Inference In Statistics*, Cambridge University Press, (2016).

[8] Shimonovich, M., Pearce, A., Thomson, H. et al. *Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking* Eur. J. Epidemiol. **36**, 873-887 (2021).

[9] T.J. VanderWeele *Explanation in Causal Inference*, Oxford University Press, (2015).

[10] C. Bycroft et al. *The UK Biobank resource with deep phenotyping and genomic data* Nature **562**, 203-209, (2018).

[11] E.T. Jaynes *Probability Theory: The Logic of Science*, Cambridge University Press, (2003).

[12] A.J. Webster, R. Clarke *Sporadic, late-onset, and multistage diseases*, medRxiv 2021.12.15.21267843, Cold Spring Harbor Laboratory Press, (2021).

[13] Webster, A.J., Gaitskell, K., Turnbull, I., Cairns B.J., Clarke R. *Characterisation, identification, clustering, and classification of disease* Scientific Reports **11**, 5405 (2021).

[14] World Health Organisation, International Statistical Classification of Diseases (ICD), www.who.int/standards/classifications/classification-of-diseases, (2021).

[15] R Core Team. *R: A Language and Environment for Statistical Computing* R Foundation for Statistical Computing, Vienna, Austria, www.R-project.org, (2020).

[16] Therneau, T.M. A Package for Survival Analysis in R, CRAN.R-project.org/package=survival, (2021).

[17] Varrichio, C. *grr: Alternative Implementations of Base R Functions*, CRAN.R-project.org/package=grr, (2016).

[18] Yang, L. Kartsonaki, C, Yao, P. *The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study*, The Lancet Public Health, **6**, Issue 12, e888 - e896.

[19] Millwood, I.Y. Walters, R.G. Mei X.W. et al. *Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China*, The Lancet, **393**, Issue 10183, 1831 - 1842.